Attovia Therapeutics (ATTO)
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company...
- Open
- 24.440
- High
- 27.660
- Low
- 24.440
- Prev. Close
- 24.200
- Volume
- 311.05K
- Turnover
- 8.22M
- Avg Price
- 26.430
- Bid/Ask Ratio
- --
- Amplitude
- 13.31%
- 52wk High
- 27.660
- Volume Ratio
- 0.00
- Turnover Ratio
- 1.18%
Attovia Therapeutics Analyst Rating
View moreForecast & Rating
Sep 3, 2026Price forecast
$42.2065.17%
Forecast & RatingStrong buy
5analysts
- Strong buy60.00%
- Buy40.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 6 hours ago
Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End on September 14th
- rttnews · Sep 4 at 09:20 AM
Biotech Stocks At 52-Week Highs - ATTO, HALO, IKT, TVTX, ATRC
- Unusual Whales · Sep 3 at 08:07 PM
Attovia Therapeutics to Participate in Upcoming Investor Conferences
- rttnews · Sep 3 at 04:50 PM
Attovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27
- Tip Ranks · Sep 3 at 03:55 PM
Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash Runway
- Market Beat · Sep 2 at 08:56 PM
Attovia Therapeutics (NASDAQ:ATTO) Releases Earnings Results
